ArticleCurrent medicinal chemistry2026
Alterations in Epoxyeicosatrienoic Acids Metabolism in Type 2 Diabetes Mellitus and Potential Association with Retinopathy Progression.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionEpoxyeicosatrienoic acids (EETs), synthesized by cytochrome P450 epoxygenases (mainly CYP2C9, CYP2J2, and CYP2S1), are vasoprotective lipid mediators that are rapidly degraded by soluble epoxide hydrolase (sEH). This study aimed to examine changes in EET metabolism in T2DM patients with and without DR to understand its potential role in disease pathogenesis and progression.
methodsTwo hundred T2DM patients (without DR), 100 with non-proliferative DR (NPDR), 100 with proliferative DR (PDR), and 200 matched healthy controls were enrolled in the study. Plasma EET levels were quantified using LC-MS/MS, and mRNA and protein levels of CYP2J2, CYP2C9, CYP2S1, and sEH were measured using qPCR and ELISA, respectively.
resultsCompared to the controls, T2DM without DR and NPDR groups, patients with PDR had significantly higher EET levels (p < 0.05). In contrast, the T2DM without DR and NPDR groups exhibited remarkably lower EET levels than controls, although this was not significant. In both groups, CYP2J2 and CYP2S1 mRNA and/or protein levels were significantly lower, suggesting suppressed EET biosynthesis. However, CYP2C9 protein levels were higher in NPDR and PDR groups than in the control group. Furthermore, in the comparison between NPDR and PDR, CYP2J2 and CYP2S1 mRNA levels were higher in PDR, whereas CYP2C9 and EPHX2 expression did not differ significantly. DISCUSSION: Plasma EET concentrations showed a tendency to be lower in the T2DM without DR and NPDR groups compared with healthy controls; however, these differences did not reach statistical significance. In contrast, patients with PDR exhibited significantly higher EET levels, suggesting stage-dependent alterations in EET metabolism during the progression of DR.
conclusionAltered EET metabolism may play a dual role in DR, influencing both early microvascular impairment and late-stage angiogenic progression.
Indexed as
Identifiers
42487591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.